title: Glass yttrium-90 microspheres for patients with colorectal liver metastases.
abstract: Total calculated uniform liver doses of up to 150 Gy were achieved using glass yttrium-90 microspheres administered via the hepatic artery and targeted to tumour using angiotensin II in seven patients with colorectal liver metastases. No toxicity was observed. Hepatic metastatic progression was delayed in six patients. Median survival was 11 months (range 5-25 + months).
authors.affiliation: University Department of Surgery, Royal Infirmary, Glasgow, UK.
authors.forename: J H
authors.initials: JH
authors.lastname: Anderson
authors.forename: J A
authors.initials: JA
authors.lastname: Goldberg
authors.forename: R G
authors.initials: RG
authors.lastname: Bessent
authors.forename: D J
authors.initials: DJ
authors.lastname: Kerr
authors.forename: J H
authors.initials: JH
authors.lastname: McKillop
authors.forename: I
authors.initials: I
authors.lastname: Stewart
authors.forename: T G
authors.initials: TG
authors.lastname: Cooke
authors.forename: C S
authors.initials: CS
authors.lastname: McArdle
mesh_terms: D000804:Angiotensin II / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000473:pathology*; D005898:Glass; D006499:Hepatic Artery; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D008863:Microspheres; D008875:Middle Aged; D011879:Radiotherapy Dosage; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D015021:Yttrium Radioisotopes; D000804:Angiotensin II